Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
NCT02903160
Completed
The purpose of this study is to determine the clinical benefits of using a rapidly cycling, non-cross reactive regimen of FDA-approved prostate cancer therapeutic agents in the management of castration resistant prostate cancer. The hypothesis is that the identification of optimal combinations and sequencing of therapies can help prevent or delay the development of therapeutic drug resistance, and can be safely tolerated.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
01/16/2024
Locations: Mount Sinai Beth Israel, New York, New York +1 locations
Conditions: Prostate Cancer
Register for Updates
M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
NCT03840902
Terminated
The main purpose of this study was to evaluate safety and efficacy in participants treated with concomitant chemoradiation therapy (cCRT) plus M7824 followed by M7824 compared to cCRT plus placebo followed by durvalumab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/12/2024
Locations: University of California Irvine Medical Center, Orange, California +103 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)
NCT01437449
Completed
Docetaxel and cetuximab are FDA-approved for the treatment of squamous cell carcinoma of the head and neck (SCCHN). Cisplatin and carboplatin, while not FDA-approved for SCCHN, have been used as standard of care in SCCHN patients in combination with other drugs. This study evaluates if weekly cisplatin and docetaxel, in combination with cetuximab, is effective in palliative treatment of patients with SCCHN. These drugs will be given intravenously weekly, repeated 3 of every 4 weeks until evidenc... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
01/07/2024
Locations: University of California Davis Medical Center, Davis, California +1 locations
Conditions: Head and Neck Cancer
Register for Updates
Drug Screening Using IMD in Bladder Cancer
NCT06204614
Not Yet Recruiting
This research study involves implanting up to 4 microdevices, each small enough to fit inside the tip of a needle, into a tumor. These devices will release microdoses (many thousands of times less than a treatment dose) of different cancer drugs into the tumor. After approximately 72 hours, the devices and small regions of surrounding tissue will be removed and studied. There will be a follow-up visit within 42 days of device removal to assess for potential safety issues or side effects.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
01/03/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Muscle Invasive Bladder Urothelial Carcinoma
Register for Updates
Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer
NCT02581943
Completed
This randomized pilot phase II trial studies the effect of pembrolizumab with or without carboplatin and paclitaxel on immune response in patients with non-small cell lung cancer that has come back or stage IIIB-IV. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/03/2024
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Register for Updates
BIO 300 Non-Small Cell Lung Cancer Study
NCT02567799
Completed
The purpose of this study is to determine the safety and effectiveness of BIO 300 Oral Suspension when used in combination with standard dose radiation therapy and chemotherapy in patients with non-small cell lung cancer. Based on preclinical data the investigators hypothesize that BIO 300 Oral Suspension will reduce the incidence of radiation-induced pneumonitis and pulmonary fibrosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/02/2024
Locations: University of Maryland School of Medicine, Baltimore, Maryland +3 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
NCT00486356
Completed
RATIONALE: Drugs used in chemotherapy, such as capecitabine, epirubicin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of capecitabine when given together with epirubicin and carboplatin in treating patients with progressive, unresectable, or metastatic ca... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
12/28/2023
Locations: University of Nebraska Medical Center, Eppley Cancer Center, Omaha, Nebraska
Conditions: Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
NCT00007865
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy combined with rituximab in treating patients who have recurrent or refractory non-Hodgkin's lymphoma.
Gender:
ALL
Ages:
Between 19 years and 120 years
Trial Updated:
12/20/2023
Locations: University of Nebraska Medical Center, Eppley Cancer Center, Omaha, Nebraska
Conditions: Lymphoma
Register for Updates
Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer
NCT03913455
Completed
This is a phase II, open-label, single arm, single-stage study. Both, chemo-sensitive and chemo-resistant patients will be enrolled and treated with 4 cycles of combination of Guadecitabine and carboplatin
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2023
Locations: Indiana Univeristy Melvin and Bren Simon Cancer Center, Indianapolis, Indiana +3 locations
Conditions: Small Cell Lung Cancer, Extensive-stage Small Cell Lung Cancer
Register for Updates
Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer
NCT03935256
Active Not Recruiting
The purpose of this trial is to evaluate the safety of sequential and concurrent carboplatin and paclitaxel with adjuvant external beam radiotherapy for locally advanced endometrial cancer. The primary objective is to assess the acute toxicities namely grade 3-4 non hematologic and grade 4 hematologic toxicities associated with the above regimen. The null hypothesis is that the unacceptable toxic response rate is ≥40%. This will be tested against a one-sided alternative that the toxicity rate is... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/15/2023
Locations: Loyola University Medical Center, Marywood, Illinois
Conditions: Endometrial Cancer
Register for Updates
Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer
NCT02621398
Active Not Recruiting
This phase I trial studies the side effects, best dose, and best way to give pembrolizumab when given together with paclitaxel, carboplatin, and radiation therapy in treating patients with stage II-IIIB non-small cell lung cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by sto... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2023
Locations: Yale Cancer Center, New Haven, Connecticut +2 locations
Conditions: Stage II Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
Register for Updates
Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib
NCT05948462
Withdrawn
This clinical trial is an open-label, single arm study evaluating the safest dose of lorlatinib in combination with standard of care chemotherapy in participants with metastatic anaplastic lymphoma kinase positive (ALK+) NSCLC who progressed on prior therapy of lorlatinib alone. The main goals of this study are to: * Evaluate the safety and tolerability of lorlatinib in combination with standard of care chemotherapy. * Evaluate how well the combination of lorlatinib and standard of care chemoth... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2023
Locations: Sarah Cannon Research Institute at HealthONE, Denver, Colorado +4 locations
Conditions: Lung Cancer, Non-small Cell Lung Cancer
Register for Updates